Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: Effects on body composition and lipids

British Journal of Cancer

Volumn 95, Issue 2, 2006, Pages 153-158

  Francini, G ^a   Petrioli, R ^a   Montagnani, A ^a   Cadirni, A ^a   Campagna, S ^a   Francini, E ^a   Gonnelli, S ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Body weight; Exemestane; Hormonal therapy; Lipid; Tamoxifen

Indexed keywords

EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BREAST CANCER; CALORIC INTAKE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; EVALUATION; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; OBESITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY COMPOSITION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIPID METABOLISM; MIDDLE AGED; OBESITY; POSTMENOPAUSE; QUALITY OF LIFE; TAMOXIFEN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33745885963     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603258     Document Type: Article

References (33)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Abu-Abid S, Szold A, Klausne J (2002) Obesity and cancer. J Med 33: 73-86
3. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R (2004) The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 15: 211-217
4. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, The ATAC (Arimidex Tamoxifen alone or in Combination) Trialists' Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802-1810
5. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L (1986) A data-based approach to diet questionnaire design and testing. Am J Epidemiol 124: 453-469
6. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH (1990) Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8: 1327-1334
7. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel III VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG, American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group (2002) American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20: 3328-3343
8. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092
9. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 92: 720-729
10. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15
11. Esteva FJ, Hortobagyi GN (2006) Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 15: 301-312
12. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320: 479-484
13. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project PI study. J Natl Cancer Inst 90: 1371-1388
14. Furr BJ, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205
15. Ganz PA (2001) Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst 30: 130-134
16. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M (1998) In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4: 2089-2093
17. Goodwin P, Esplen MJ, Butler K, Winocur J, Pritchard K, Brazel S, Gao J, Miller A (1998) Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. Breast Cancer Res Treat 48: 53-64
18. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802
19. Goss PE, Strasser K (2001) Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881-894
20. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longeope C, Speizer FE (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87: 1297-1302
21. Hoskin PJ, Ashley S, Yarnold JR (1992) Weight gain after primary surgery for breast cancer-effect of tamoxifen. Breast Cancer Res Treat 22: 129-132
22. Levine EG, Raczynski JM, Carpenter JT (1991) Weight gain with breast cancer adjuvant treatment. Cancer 67: 1954-1959
23. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23: 5126-5137
24. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopusal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1327-1332
25. Malinovszky KM, Cameron D, Douglas S, Love C, Leonard T, Dixon JM, Hopwood P, Leonard RC (2004) Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). The Breast 13: 363-368
26. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H (2005) The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 93: 61-66
27. Meier CR, Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45: 608-612
28. Rose DP, Connolly JM, Chlebowski RT, Buzzard IM, Wynder EL (1993) The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. Breast Cancer Res Treat 27: 253-262
29. Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN, Paffenbarger Jr RS (1985) Physical activity assessment methodology in the Five-City project. Am J Epidemiol 121: 91-106
30. Selby C (1990) Sex hormone binding globulin: origin, function, and clinical significance. Ann Clin Biochem 27: 532-541
31. Siiteri PK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 45(Suppl 1): 277-282
32. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348: 2431-2442
33. Yeu W, Santen RJ (1996) Aromatase inhibitors: rationale for use following antiestrogen therapy. Semin Oncol 23(Suppl 9): 21-27